Arcutis Biotherapeutics develops topical therapies targeting immune-mediated skin diseases, utilizing a drug development platform focused on biologically validated targets. The company addresses the lack of effective treatments for chronic inflammatory skin conditions, improving patient outcomes and simplifying disease management.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with chronic inflammatory skin diseases lack effective topical treatments, leading to persistent challenges in disease management and impacting their quality of life. Existing treatments may not adequately address the underlying biological mechanisms or provide sufficient relief from symptoms.
Solution
Arcutis Biotherapeutics is developing topical therapies for immune-mediated skin diseases, utilizing a drug development platform focused on biologically validated targets. The company aims to address the unmet needs of patients with chronic inflammatory skin conditions by providing innovative treatments that improve patient outcomes and simplify disease management. Their approach involves a deep understanding of the challenges faced by both patients and healthcare professionals, allowing them to create targeted therapies that deliver meaningful results.
Target Audience
The primary audience includes patients with chronic inflammatory skin diseases and healthcare professionals specializing in medical dermatology.
Features
- Focus on biologically validated targets in immuno-dermatology
- Development of novel topical therapies for chronic inflammatory skin diseases
- Addressing unmet needs in medical dermatology through meaningful innovation